| UHC Medicaid Medical & Drug | Roctavian® (Valoctocogene Roxaparvovec-Rvox) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Ryplazim® (Plasminogen, Human-Tvmh) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Saphnelo® (Anifrolumab-Fnia) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Scenesse® (Afamelanotide) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Self-Administered Medications – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Simponi Aria® (Golimumab) Injection for Intravenous Infusion – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Skin and Soft Tissue Substitutes – Community Plan Medical Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Skyrizi® (Risankizumab-Rzaa) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Sodium Hyaluronate – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Somatostatin Analogs – Community Plan Medical Benefit Drug Policy | 2026-04-01 |